H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report)’s stock price was down 49.5% during trading on Tuesday . The company traded as low as $2.02 and last traded at $2.02. Approximately 400 shares traded hands during trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Trading Down 49.5 %
The business’s fifty day simple moving average is $2.02 and its 200 day simple moving average is $2.02.
H-CYTE Company Profile
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Featured Articles
- Five stocks we like better than H-CYTE
- Basic Materials Stocks Investing
- 3 Mid-Cap Medical Stocks Outperforming the Market
- How to Find Undervalued Stocks
- The Top-Ranked Insider Buys From April by Market Cap
- How to Calculate Return on Investment (ROI)
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
